The Siegfried Group is a global life sciences company, headquartered in Switzerland, with facilities located in Switzerland, the USA, Malta, China, Germany and France.
In 2017, the company achieved net sales of CHF 750.5 million and currently employs approximately 2300 people. Siegfried Holding AG is publicly listed on the Swiss Stock Exchange in Zurich (SIX: SFZN).
Siegfried is active in primary and secondary drug manufacturing. The company develops and manufactures active pharmaceutical ingredients for pharmaceutical clients with R&D programs, related intermediates and controlled substances. Siegfried also offers development and production of finished dosage forms, including sterile fillings.